Similar articles for PMID: 23716303

Year	Number of Results
2001	1
2003	1
2004	1
2005	4
2006	7
2007	5
2008	4
2009	5
2010	4
2011	3
2012	2
2013	7
2014	11
2015	8
2016	5
2017	9
2018	10
2019	6
2020	6
2021	3
2022	2
2023	1
2024	0

1

New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.

Takahashi T, Serada S, Ako M, Fujimoto M, Miyazaki Y, Nakatsuka R, Ikezoe T, Yokoyama A, Taguchi T, Shimada K, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M, Doki Y, Naka T, Nishida T. Takahashi T, et al. Int J Cancer. 2013 Dec 1;133(11):2737-43. doi: 10.1002/ijc.28282. Epub 2013 Jun 14. Int J Cancer. 2013. PMID: 23716303 Free article.

2

Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.

Thao le B, Vu HA, Yasuda K, Taniguchi S, Yagasaki F, Taguchi T, Watanabe T, Sato Y. Thao le B, et al. Cancer Biol Ther. 2009 Apr;8(8):683-8. doi: 10.4161/cbt.8.8.7779. Cancer Biol Ther. 2009. PMID: 19417561

3

Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.

Sakurama K, Noma K, Takaoka M, Tomono Y, Watanabe N, Hatakeyama S, Ohmori O, Hirota S, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Tanaka N, Naomoto Y. Sakurama K, et al. Mol Cancer Ther. 2009 Jan;8(1):127-34. doi: 10.1158/1535-7163.MCT-08-0884. Mol Cancer Ther. 2009. PMID: 19139121

4

SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.

Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, Naka T. Sugase T, et al. Gastric Cancer. 2018 Nov;21(6):968-976. doi: 10.1007/s10120-018-0822-1. Epub 2018 Apr 5. Gastric Cancer. 2018. PMID: 29623544

5

Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.

Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB. Chen W, et al. Cancer Res. 2017 Sep 15;77(18):5107-5117. doi: 10.1158/0008-5472.CAN-17-0917. Epub 2017 Jul 31. Cancer Res. 2017. PMID: 28760855

6

miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.

Huang WK, Akçakaya P, Gangaev A, Lee L, Zeljic K, Hajeri P, Berglund E, Ghaderi M, Åhlén J, Bränström R, Larsson C, Lui WO. Huang WK, et al. Exp Cell Res. 2018 Oct 1;371(1):287-296. doi: 10.1016/j.yexcr.2018.08.028. Epub 2018 Aug 24. Exp Cell Res. 2018. PMID: 30149002 Free article.

7

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Antonescu CR, et al. Clin Cancer Res. 2005 Jun 1;11(11):4182-90. doi: 10.1158/1078-0432.CCR-04-2245. Clin Cancer Res. 2005. PMID: 15930355

8

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.

Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW. Javidi-Sharifi N, et al. Cancer Res. 2015 Mar 1;75(5):880-91. doi: 10.1158/0008-5472.CAN-14-0573. Epub 2014 Nov 28. Cancer Res. 2015. PMID: 25432174 Free PMC article.

9

Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.

Gordon PM, Fisher DE. Gordon PM, et al. J Biol Chem. 2010 May 7;285(19):14109-14. doi: 10.1074/jbc.M109.078592. Epub 2010 Mar 15. J Biol Chem. 2010. PMID: 20231287 Free PMC article.

10

Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.

Noma K, Naomoto Y, Gunduz M, Matsuoka J, Yamatsuji T, Shirakawa Y, Nobuhisa T, Okawa T, Takaoka M, Tomono Y, Hiroyuki O, Gunduz E, Tanaka N. Noma K, et al. Oncol Rep. 2005 Sep;14(3):645-50. Oncol Rep. 2005. PMID: 16077968

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year